Venoms don't kill.
They target.
So do drugs.
"Venom peptides don't destroy.
They Bind, Block, Modulate"
Evolution had a 700M-year head start. We're catching up.
Venoms are nature’s most information-dense drug library—vast, precise, and underexplored. We combine high-resolution venomics with AI to decode targets and generate clinically actionable leads.
<0.1% explored.
A library larger than all synthetic chemistry—waiting.
FDA-Approved Venom Therapeutics
Ziconotide (Prialt)
Derived from cone snail Conus magus toxin ω-conotoxin. A pioneering non-opioid analgesic for severe chronic pain.
Conus magus · FDA Approved 2004
Exenatide (Byetta)
Based on exendin-4 from Gila monster Heloderma suspectum saliva. The foundational GLP-1 receptor agonist for type 2 diabetes.
Heloderma suspectum · FDA Approved 2005
Captopril
Inspired by bradykinin-potentiating peptides in Brazilian pit viper Bothrops jararaca venom. The first ACE inhibitor to hit the market.
Bothrops jararaca · FDA Approved 1981
The Venomics Advantage
Voltage-gated ion channels (pain, epilepsy), GPCRs (metabolic, cardiovascular), and Coagulation factors (thrombosis).
Snakes
Phospholipases, metalloproteinases, three-finger toxins — cardiovascular, neurology
Scorpions
Chlorotoxin, iberiotoxin — oncology, pain, ion channel targets
Spiders
Acylpolyamines, knottins — pain, epilepsy, anti-infective
Cone Snails
Conotoxins — one of the richest peptide sources known, analgesics
Cnidarians
Sea anemone toxins — ion channel blockers, autoimmune disease
Lizards & Reptiles
Exendins, helodermins — metabolic disease, GLP-1 pathway
The Venomics AI Discovery Engine
A four-layer platform that connects India’s venom biodiversity with multi-omics, generative AI, and translational screening to discover next-generation therapeutics.
Venom Bank
India’s curated repository of animal venoms from medically important species across the subcontinent — each linked to specimen identity, geography, and ecology.
Venom Atlas
A multi-omics database connecting venom composition with toxin sequences, species biology, and experimentally validated bioactivity — searchable by species, toxin family, or disease target.
Venom LLM
A purpose-built AI trained on toxin sequence–activity pairs to predict biological activity, score target selectivity, and generate optimised peptide leads.
Venomics Library
10,000+ natural toxins and synthetic analogues screened against 100+ disease-relevant targets, bridging computational prediction with preclinical development.
Automation Vision
Humanoids + AI for autonomous drug discovery
We envision a fully automated discovery ecosystem where humanoid robots, laboratory automation, and AI agents accelerate every stage of therapeutic development — from venom fractionation and molecular screening to candidate optimisation and preclinical validation.
From fang to pharmacy
An end-to-end platform spanning field ecology, computational biology, and translational drug discovery.
Biodiversity Atlas
A venom biodiversity resource from the Indian subcontinent, anchored by medically and biologically important species.
Evolutionary Venomics
Tracing how toxins diversify across species, geography, ecology, and evolutionary time.
Venom Biochemistry & Pharmacology
Proteomics, fractionation, biochemical assays, and pharmacology to decode venom activity.
AI & Large Language Models
AI workflows for venom annotation, target prediction, molecular prioritisation, and design.
Antibody Discovery & Engineering
Discovery, optimisation, and engineering of antibodies against medically important toxins.
Drug Discovery & Development
Connecting toxin biology and translational science to advance selective therapeutic leads.
Small-Molecule Drugs & Phytocompounds
Screening natural products, phytocompounds, and synthetic molecules as venom inhibitors.
Partnerships & Licensing
Academic, clinical, industry, and regulatory collaborations for validation and licensing.
Meet the minds behind the mission
A multidisciplinary team spanning toxinology, computational biology, and machine learning.
KS
An evolutionary biologist and founder building at the intersection of biodiversity, deep science, and drug discovery. Based at IISc, Bengaluru, his research group studies animal venoms and develops innovative treatments for snakebite, including monoclonal antibodies and small-molecule therapeutics. Through Venomics AI, he is creating a scalable biodiscovery platform that transforms nature’s toxins into tomorrow’s medicines.
VP
An AI expert and technology leader building at the intersection of computation and drug discovery. He leads the development of advanced machine learning platforms that analyse complex biological data, enabling the identification and optimisation of novel therapeutic candidates. As co-founder of Venomics.AI, he drives the company’s computational strategy, transforming large-scale venom datasets into actionable insights for next-generation medicines.
Advisors & Collaborators
World-Class Scientists Guiding and Validating Our Science.
+ Expanding Advisory Board
Our advisory network is growing — reach out if you'd like to collaborate.
Peer-reviewed science
Latest Developments
Key milestones, funding announcements, and press features from the Venomics AI team.
Venomics AI Conceptualized
Kartik and Vinay met in India after 15 years and Venomics AI was conceptualized.
Company Milestone
~$3M Funding Raised
Venomics AI has managed to raise $3M in funding on 10th April 2026.
Funding Announcement
Synthetic antibody to neutralise snake bite toxins
Researchers at EVL successfully developed a broadly neutralizing antibody targeting conserved regions of snake venom neurotoxins.
The Hindu
Let's build the future of medicine together
Whether you're an investor, partner, scientist, or patient advocate — we want to hear from you.
info@venomics.aiLocation
Indian Institute of Science, Bengaluru 560012, India
Partnerships & Licensing
info [at] venomics.ai
Send us a message
Email draft ready
Your email app should open with a drafted message to info@venomics.ai.